Pipeline — registered trials by phase
A Long-term Follow-up Study in Patients Who Received BEAM-101
— · Hemoglobinopathy, Sickle Cell Disease · Recruiting · est. 2043-02-12
This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of BEAM-103 in Healthy Subjects
— · Healthy Subjects, Healthy Participant Study · Recruiting · est. 2026-01-29
A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)
— · Alpha 1-Antitrypsin Deficiency · Recruiting · est. 2028-05
A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
— · Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Leukemia · Active Not Recruiting · est. 2026-12
BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease
— · Sickle Cell Disease · Active Not Recruiting · est. 2028-02
A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa)
— · Glycogen Storage Disease Type Ia · Recruiting · est. 2027-12-30
No registered trials in this stage.
No approved products listed under this sponsor in Drugs@FDA (partnered or subsidiary products may be listed elsewhere).
Source: ClinicalTrials.gov (trials where Beam Therapeutics is lead sponsor; 6 active or completed) and Drugs@FDA (0 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.
SEC filings — insider trading forms excluded
- SCHEDULE 13G/A2026-08-14SCHEDULE 13G/A
- SCHEDULE 13G/A2026-08-13SCHEDULE 13G/A
- 10-Q2026-08-04Quarterly report
- 8-K2026-08-04Current report (material event)
- 8-K2026-06-08Current report (material event)
- 10-Q2026-05-07Quarterly report
- 8-K2026-05-07Current report (material event)
- SCHEDULE 13G2026-04-29SCHEDULE 13G
- ARS2026-04-17Annual report to holders
- DEFA14A2026-04-17DEFA14A
- DEF 14A2026-04-17Proxy statement
- SCHEDULE 13G/A2026-03-26SCHEDULE 13G/A
- 8-K2026-03-05Current report (material event)
- S-82026-02-24Employee stock plan
- 10-K2026-02-24Annual report
- 8-K2026-02-24Current report (material event)
- 8-K2026-02-12Current report (material event)
- SCHEDULE 13G2026-02-09SCHEDULE 13G
- 8-K2026-02-05Current report (material event)
- SCHEDULE 13G/A2026-02-05SCHEDULE 13G/A
- SCHEDULE 13G/A2026-02-05SCHEDULE 13G/A
- SCHEDULE 13G/A2026-02-03SCHEDULE 13G/A
- 8-K2026-01-12Current report (material event)
- 8-K2025-12-11Current report (material event)
- SCHEDULE 13G/A2025-11-05SCHEDULE 13G/A
- 10-Q2025-11-04Quarterly report
- 8-K2025-11-04Current report (material event)
- SCHEDULE 13G/A2025-08-07SCHEDULE 13G/A
- SCHEDULE 13G/A2025-08-06SCHEDULE 13G/A
- 10-Q2025-08-05Quarterly report
- 8-K2025-08-05Current report (material event)
- 8-K2025-07-03Current report (material event)
- 8-K2025-06-06Current report (material event)
- SCHEDULE 13G/A2025-05-15SCHEDULE 13G/A
- SCHEDULE 13G/A2025-05-13SCHEDULE 13G/A
- 10-Q2025-05-06Quarterly report
- 8-K2025-05-06Current report (material event)
- ARS2025-04-18Annual report to holders
- DEFA14A2025-04-18DEFA14A
- DEF 14A2025-04-18Proxy statement
Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.